M. , E. Cancer-de-l-'ovaire, and .. , 39 -STK11, aussi appelé PJS ou LKB1: la mutation de ce gène est retrouvée chez les personnes atteintes du syndrome de Peutz-Jeghers

. Décembre, Quelques chiffres sur le cancer du sein. Disponibles sur le site http, 2009.

. Cancer-du-sein, Les prédispositions génétiques Disponibles sur le site http://www.ecancer .fr/les-cancers/cancer-du-sein/les-facteurs-de-risque/les-predispositions-genetiques

J. Levêque, C. Dugast, J. Blanchot, and J. Grall, Disponibles sur le site http://www.invs.sante.fr/fr/Espace-presse/Communiques-de-presse Problems raised by the gynaecologic management of women with BRCA1&2 mutations, Les chiffres 2011 du cancer, pp.370-377, 2003.

P. Bork, K. Hofman, P. Bucher, and A. Neuwald, A superfamily of conserved domains in DNA damage-responsive cell cycle checkpoint proteins., The FASEB Journal, vol.11, issue.1, pp.68-76, 1997.
DOI : 10.1096/fasebj.11.1.9034168

L. Hilakivi-clarke, Estrogens, BRCA1, and breast cancer, Cancer Res, vol.1, issue.60, pp.4993-5001, 2000.

J. Gudas, T. Li, and H. Nguyen, Cell cycle regulation of BRCA1 messenger RNA in human breast epithelial cells, Cell Growth Differ, vol.7, pp.717-740, 1996.

R. Scully, J. Chen, R. Ochs, K. Keegan, M. Hoesktra et al., Dynamic Changes of BRCA1 Subnuclear Location and Phosphorylation State Are Initiated by DNA Damage, Cell, vol.90, issue.3
DOI : 10.1016/S0092-8674(00)80503-6

S. Fan, Y. Ma, C. Wang, R. Yuan, Q. Meng et al., Role of direct interaction in BRCA1 inhibition of estrogen receptor activity, Oncogene, vol.96, issue.1, pp.77-87, 2001.
DOI : 10.1074/jbc.273.39.25388

S. Fan, J. Wang, R. Yuan, Y. Ma, Q. Meng et al., BRCA1 Inhibition of Estrogen Receptor Signaling in Transfected Cells, Science, vol.284, issue.5418, pp.1354-1360, 1999.
DOI : 10.1126/science.284.5418.1354

A. Martin and B. Weber, Genetic and Hormonal Risk Factors in Breast Cancer, Journal of the National Cancer Institute, vol.92, issue.14, pp.1126-1161, 2000.
DOI : 10.1093/jnci/92.14.1126

S. Sharan, M. Morimatsu, and U. Albrecht, Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2 Managing hereditary ovarian cancer risk, Nature Cancer, vol.386, issue.86, pp.804-101697, 1997.

D. Ford, D. Easton, and D. Bishop, Risks of cancer in BRCA1-mutation carriers, The Lancet, vol.343, issue.8899, pp.692-697, 1994.
DOI : 10.1016/S0140-6736(94)91578-4

P. Chappuis, P. Nethercot, and W. D. Foulkes, Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer, Seminars in Surgical Oncology, vol.91, issue.4, pp.287-95, 2000.
DOI : 10.1002/ajmg.1320560305

G. Holveck, Aspacts anatomo-cliniques et pronostiques des cancers du sein et de l

G. Colfitz, W. Willet, and M. Stampfer, Menopause and the risk of coronary heart disease in women 1105-10. 21. Un cancer de l' ovaire, qu'est-ce-que-c'est? Cancer Info. Disponible sur le site http, N Engl J Med, vol.20, issue.31618, 1987.

Y. Miki, J. Swensen, and D. Shattuck-eidens, A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1, Science, vol.266, issue.5182, pp.66-71, 1994.
DOI : 10.1126/science.7545954

R. Wooster, S. Neuhausen, and J. Mangion, Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13, Science, vol.265, issue.5181, pp.2088-90, 1994.
DOI : 10.1126/science.8091231

M. Spillman and A. Bowcock, BRCA1 and BRCA2 mRNA levels are co-ordinately elevated in human breast cancer cells in response to oestrogen, Oncogene, vol.13, pp.1639-1684, 1996.

R. Eeles, Future possibilities in the prevention of breast cancer: Intervention strategies in BRCA1 and BRCA2 mutation carriers, Breast Cancer Research, vol.16, issue.13, pp.283-90, 2000.
DOI : 10.1200/JCO.1998.16.7.2417

H. Jenrstrom, C. Lerman, and P. Ghadirian, Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2, Lancet, vol.354, pp.1846-50, 1999.

R. Wooster, G. Bignell, and J. Lancaster, Identification of the breast cancer susceptibility gene BRCA2, Nature, vol.72, issue.6559, pp.789-92, 1995.
DOI : 10.1038/bjc.1995.493

P. Saltel, V. Bonadona, H. Lynch, E. Silva, C. Snyder et al., Oncogenetique et psycho-oncologie: une collaboration recommandée Oncologie Hereditary breast cancer: part I. Diagnosing Hereditary breastcancer syndromes Meta-analysis of BRCA1 and BRCA2 penetrance, Breast J J Clin Oncol, vol.7, issue.25, pp.1-8, 2005.
DOI : 10.1007/s10269-005-0191-3

K. Offit, BRCA Mutation Frequency and Penetrance: New Data, Old Debate, JNCI: Journal of the National Cancer Institute, vol.98, issue.23, pp.1675-1682, 2006.
DOI : 10.1056/NEJM200107193450301

URL : https://academic.oup.com/jnci/article-pdf/98/23/1675/7688143/djj500.pdf

C. Begg, R. Haile, and A. Borg, Variation of breast cancer risk among BRCA1

A. Antoniou, P. Pharoah, and S. Narod, Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies, The American Journal of Human Genetics, vol.72, issue.5, pp.1117-1147, 2003.
DOI : 10.1086/375033

F. Liebens, C. B. Pastijn, A. Rozenberg, and S. , Management of BRCA1/2 associated breast cancer: A systematic qualitative review of the state of knowledge in 2006, European Journal of Cancer, vol.43, issue.2, pp.238-57, 2007.
DOI : 10.1016/j.ejca.2006.07.019

B. Zafrani, N. Fabre, A. Fourquet, M. Robson, P. Chappuis et al., Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breastconserving surgery and radiotherapy A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment Ten-year multi-institutional results of breastconservingsurgeryandradiotherapyinBRCA1/2associatedtageI/II breast cancer, Eur J Cancer Cancer Res J Clin Oncol, vol.41, issue.24, pp.2304-2315, 2004.

B. Haffty, E. Harrold, and A. Khan, Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status, The Lancet, vol.359, issue.9316, pp.1471-1478, 2002.
DOI : 10.1016/S0140-6736(02)08434-9

K. Metcalfe, H. Lynch, and P. Ghadirian, Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers, British Journal of Cancer, vol.351, issue.9, pp.2328-2363, 2004.
DOI : 10.1016/S0140-6736(97)07065-7

D. Ford, D. Easton, and M. Stratton, and the Breast Cancer Linkage Consortium., Genetic heterogeneity and penetrance analusis of the BRCA1 and BRCA2 genes in breast cancer families, Am J Hum Genet, vol.62, pp.679-89, 1998.

G. Schwartz, K. Hughes, and H. Lynch, Proceedings of the International Consensus Conference on Breast Cancer Risk, Genetics, & Risk Management, April, 2007, Cancer, vol.113, issue.10, pp.2627-2664, 2007.
DOI : 10.1002/cncr.23903

J. Khatcheressian, A. Wolff, and T. Smith, American Society of Clinical Oncology 2006 Update of the Breast Cancer Follow-Up and Management Guidelines in the Adjuvant Setting, Journal of Clinical Oncology, vol.24, issue.31, pp.5091-5098, 2006.
DOI : 10.1200/JCO.2006.08.8575

F. Eisinger, C. Julian-reynier, and H. Sobol, Acceptability of Prophylactic Mastectomy in Cancer-Prone Women, JAMA: The Journal of the American Medical Association, vol.283, issue.2, pp.202-205, 2000.
DOI : 10.1001/jama.283.2.202

J. Cuzick, T. Powles, and U. Veronesi, Overview of the main outcomes in breast-cancer prevention trials, The Lancet, vol.361, issue.9354, pp.296-300, 2003.
DOI : 10.1016/S0140-6736(03)12342-2

J. Cuzick, J. Forbes, and R. Edwards, First results from the International Breast Cancer Intervention Study (IBIS-1): a randomised prevention trial, Lancet, vol.360, pp.817-841, 2002.

J. Cuzick, J. Forbes, and I. Sestak, Long-Term Results of Tamoxifen Prophylaxis for Breast Cancer--96-Month Follow-up of the Randomized IBIS-I Trial, JNCI Journal of the National Cancer Institute, vol.163, issue.8, pp.272-82, 2007.
DOI : 10.1007/978-3-642-55647-0_9

C. Phelan, A low frequency of non-founder BRCA1 mutations in Ashkenazi Jewish breast-ovarian cancer families, Human Mutation, vol.36, issue.5, pp.352-357, 2002.
DOI : 10.1093/jnci/91.14.1241

S. Narod, BRCA mutations in the management of breast cancer: the state of the art, Nature Reviews Clinical Oncology, vol.376, issue.12
DOI : 10.4161/cbt.8.7.7968

J. Gronwald, N. Tung, and W. Foulkes, Tamoxifen and contralateral breast cancer inBRCA1 andBRCA2 carriers: An update, International Journal of Cancer, vol.96, issue.9, pp.2281-2285, 2006.
DOI : 10.1002/ijc.21536

URL : http://onlinelibrary.wiley.com/doi/10.1002/ijc.21536/pdf

D. Schrag, K. Kuntz, J. Garber, and J. Weeks, Life Expectancy Gains From Cancer Prevention Strategies for Women With Breast Cancer and <EMPH TYPE="ITAL">BRCA1</EMPH> or <EMPH TYPE="ITAL">BRCA2</EMPH> Mutations, JAMA, vol.283, issue.5, pp.617-641, 2000.
DOI : 10.1001/jama.283.5.617

M. Robson, Treatment of Hereditary Breast Cancer, Seminars in Oncology, vol.34, issue.5, pp.384-91, 2007.
DOI : 10.1053/j.seminoncol.2007.07.011

A. Berchuck, M. Carney, J. Lancaster, J. Marks, and A. Futreal, Familial Breast-Ovarian Cancer Syndromes, Clinical Obstetrics and Gynecology, vol.41, issue.1, pp.157-66, 1998.
DOI : 10.1097/00003081-199803000-00022

S. Lakhani, S. Manek, and F. Penault-llorca, Pathology of ovarian cancers in BRCA1 and BRCA2 carriers Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer Feasibility of performing chemoprevention trials in women at elevated risk of ovarian carcinoma: initial examination of cell as a chemopreventive agent, Clin Cancer Res J Clin Oncol Gynecol Oncol, vol.10, issue.98, pp.2473-81, 2004.

J. Mclaughlin, H. Risch, and J. Lubinski, Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study, The Lancet Oncology, vol.8, issue.1, pp.26-34, 2007.
DOI : 10.1016/S1470-2045(06)70983-4

T. Rebbeck, H. Lynch, and S. Neuhausen, Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers, European Journal of Cancer, vol.38, pp.1616-1622, 2002.
DOI : 10.1016/S0959-8049(02)00269-1

N. Kauff, J. Satagopan, and M. Robson, Risk-Reducing Salpingo-Oophorectomy in Women With a BRCA1 or BRCA2 Mutation, Obstetrical & Gynecological Survey, vol.57, issue.9, pp.1609-1615, 2002.
DOI : 10.1097/00006254-200209000-00016

A. Eisen, J. Lubinski, and J. Klijn, Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study, J

A. Finch, M. Beiner, and J. Lubinski, Salpingo-oophorectomy and the Risk of Ovarian, Fallopian Tube, and Peritoneal Cancers in Women with a BRCA1 or BRCA2 Mutation, Obstetrical & Gynecological Survey, vol.62, issue.1, pp.7491-6185, 2005.
DOI : 10.1097/01.ogx.0000251480.69322.50

F. Eisinger, D. Stoppa-lyonnet, and C. Lasset, Comparison of physicians and cancer prone women's attitudes about breast/ovarian prophylactic surgery. Results from two national surveys, Familial Cancer, vol.1, issue.3/4, pp.157-62, 2001.
DOI : 10.1023/A:1021113715998

C. Julian-reynier, L. Bouchard, and D. Evans, Women's attitudes toward preventive strategies for hereditary breast or ovarian carcinoma differ from one country to another, Cancer, vol.15, issue.4, pp.959-68, 2001.
DOI : 10.1155/1999/140498

L. Scheuer, N. Kauff, and M. Robson, Outcome of Preventive Surgery and Screening for Breast and Ovarian Cancer in BRCA Mutation Carriers, Journal of Clinical Oncology, vol.20, issue.5, pp.1260-1268, 2002.
DOI : 10.1200/JCO.20.5.1260

N. Kauff, S. Domchek, and T. Friebel, Risk-Reducing Salpingo-Oophorectomy for the Prevention of BRCA1- and BRCA2-Associated Breast and Gynecologic Cancer: A Multicenter, Prospective Study, Journal of Clinical Oncology, vol.26, issue.8, pp.1331-1338, 2008.
DOI : 10.1200/JCO.2007.13.9626

K. Metcalfe, H. Lynch, and P. Ghadirian, Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers Breast Cancer Res Treat The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study, Gynecol Oncol, vol.127104, issue.1, pp.287-96, 2007.

T. Rebbeck, N. Kauff, and S. Domchek, Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation Carriers, JNCI Journal of the National Cancer Institute, vol.356, issue.25, pp.80-87, 2009.
DOI : 10.1056/NEJMoa071513

P. Willsher, A. Ali, and L. Jackson, LAPAROSCOPIC OOPHORECTOMY IN THE MANAGEMENT OF BREAST DISEASE, ANZ Journal of Surgery, vol.87, issue.8, pp.670-672, 2008.
DOI : 10.1111/j.1445-2197.2008.04614.x

T. Colgan, S. Boerner, J. Murphy, D. Cole, S. Narod et al., Peritoneal Lavage Cytology: An Assessment of Its Value during Prophylactic Oophorectomy, Gynecologic Oncology, vol.85, issue.3, pp.397-403, 2002.
DOI : 10.1006/gyno.2002.6638

R. Eitan, R. Soslow, and O. Lin, The significance of cytological mesothelial atypia diagnosed from peritoneal washings performed during risk-reducing salpingo-oophorectomy, Gynecologic Oncology, vol.102, issue.2
DOI : 10.1016/j.ygyno.2005.12.021

M. Casey and C. Bewtra, Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations, Familial Cancer, vol.85, issue.3-4, pp.265-81, 2004.
DOI : 10.3181/00379727-217-44204

L. Gerritzen, J. Grefte, N. Hoogerbrugge, J. Bulten, L. Massuger et al., A substantial part of the fallopian tube is left after standard prophylactic bilateral salpingo-oophorectomy, International Journal of Gynecological Cancer, vol.16, issue.5, pp.1940-1944, 2006.
DOI : 10.1111/j.1525-1438.2006.00720.x

M. Callahan, C. Crum, and F. Medeiros, -Positive Women Undergoing Surgery for Ovarian Cancer Risk Reduction, Journal of Clinical Oncology, vol.25, issue.25, pp.3985-90, 2007.
DOI : 10.1200/JCO.2007.12.2622

F. Medeiros, M. Muto, and Y. Lee, The Tubal Fimbria Is a Preferred Site for Early Adenocarcinoma in Women With Familial Ovarian Cancer Syndrome, The American Journal of Surgical Pathology, vol.30, issue.2, pp.230-236, 2006.
DOI : 10.1097/01.pas.0000180854.28831.77

R. Goshen, W. Chu, and L. Elit, Is Uterine Papillary Serous Adenocarcinoma a Manifestation of the Hereditary Breast???Ovarian Cancer Syndrome?, Gynecologic Oncology, vol.79, issue.3, pp.477-81, 2000.
DOI : 10.1006/gyno.2000.6003

T. Biron-shental, L. Drucker, M. Altaras, J. Bernheim, and A. Fishman, High incidence of BRCA1???2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma, European Journal of Surgical Oncology (EJSO), vol.32, issue.10, pp.1097-100, 2006.
DOI : 10.1016/j.ejso.2006.03.032

O. Lavie, A. Ben-arie, and A. Pilip, BRCA2 germline mutation in a woman with uterine serous papillary carcinoma???Case report, 81. NCCN. Genetic/familial high risk assessment :Breast and ovarian, pp.486-494, 2005.
DOI : 10.1016/j.ygyno.2005.06.009

. Available, nccn.org/professionals/physician_gls/PDF/genetics_screening.pdf 82. NICE. Familial breast cancer: the classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care Available, 2006.

T. Rebbeck, T. Friebel, and T. Wagner, Mutation Carriers: The PROSE Study Group, CG41NICEguidance.pdf 83, pp.7804-7814, 2005.
DOI : 10.1200/JCO.2004.00.8151

V. Jacoby, D. Grady, and G. Sawaya, Oophorectomy as a risk factor for coronary heart disease Prophylactic ovariectomy: a true pseudo good idea, Am J Obstet Gynecol, vol.200, 2009.

G. Parker, W. Broder, M. Chang, and E. , Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurse's health study, Obstet Gynecol, vol.345, issue.113, pp.1027-1064, 2009.

F. Atsma, M. Bartelink, D. Grobbee, and Y. Schow, Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis, Menopause, vol.13, issue.2
DOI : 10.1097/01.gme.0000218683.97338.ea

T. Michelsen, A. Pripp, S. Tonstad, C. Tropé, and A. Dørum, Metabolic syndrome after risk-reducing salpingo-oophorectomy in women at high risk for hereditary breast ovarian cancer: A controlled observational study, European Journal of Cancer, vol.45, issue.1, pp.82-91, 2009.
DOI : 10.1016/j.ejca.2008.09.028

L. Melton, Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause, Neurology, vol.69, issue.11, pp.1074-83, 2007.

E. Hogervorst and S. Bandelow, Should surgical menopausal women be treated with estrogens to decrease the risk of dementia?, Neurology, vol.69, issue.11, pp.1070-71, 2007.
DOI : 10.1212/01.wnl.0000279584.03800.3d

K. Holli, J. Isola, and J. Cuzick, Low biologic aggressiveness in breast cancer in women using hormone replacement therapy., Journal of Clinical Oncology, vol.16, issue.9, pp.3115-3120, 1998.
DOI : 10.1200/JCO.1998.16.9.3115

R. Chlebowski, S. Hendrix, and R. Langer, Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal Women, JAMA, vol.289, issue.24, pp.3243-3253, 2003.
DOI : 10.1001/jama.289.24.3243

M. Stefanick, G. Anderson, and K. Margolis, Effects of Conjugated Equine Estrogens on Breast Cancer and Mammography Screening in Postmenopausal Women With Hysterectomy, JAMA, vol.295, issue.14, pp.1647-57, 2006.
DOI : 10.1001/jama.295.14.1647

R. Chlebowski and R. Prentice, Menopausal Hormone Therapy in BRCA1 Mutation Carriers: Uncertainty and Caution, JNCI Journal of the National Cancer Institute, vol.22, issue.6, pp.1341-1344, 2008.
DOI : 10.1200/JCO.2004.01.926

A. Eisen, J. Lubinski, and J. Gronwald, Hormone Therapy and the Risk of Breast Cancer in BRCA1 Mutation Carriers, JNCI Journal of the National Cancer Institute, vol.1001, issue.9574, pp.1361-1368, 2008.
DOI : 10.1016/S0140-6736(07)60534-0

J. Rabban, M. Barnes, and L. Chen, Ovarian pathology in riskreducing salpingo? oophorectomies from women with BRCA mutations, emphazing the differential diagnosis of occult primary and metastatic carcinoma, Am J Surg, vol.33, pp.1125-1161, 2009.

D. Harber, Mutations, New England Journal of Medicine, vol.346, issue.21, pp.1660-1661, 2002.
DOI : 10.1056/NEJMed020044

M. Greene, P. Mai, and P. Schwartz, Does bilateral salpingectomy with ovarian retention warrant consideration as a temporary bridge to risk-reducing bilateral oophorectomy in BRCA1/2 mutation carriers?, American Journal of Obstetrics and Gynecology, vol.204, issue.1, pp.19-20, 2011.
DOI : 10.1016/j.ajog.2010.05.038

J. Madalinska, B. Van, and E. Bleiker, Mutation Carriers, Journal of Clinical Oncology, vol.25, issue.3, pp.301-308, 2007.
DOI : 10.1200/JCO.2006.07.4922

E. Bleiker, D. Hahn, and N. Aaronson, Psychosocial Issues in Cancer Genetics, Acta Oncologica, vol.42, issue.4, pp.276-86, 2003.
DOI : 10.1080/02841860310004391

I. Van-oostram, H. Meijers-heijboer, and L. Lodder, Long-Term Psychological Impact of Carrying a BRCA1/2 Mutation and Prophylactic Surgery: A 5-Year Follow-Up Study, Journal of Clinical Oncology, vol.21, issue.20, pp.3867-74, 2003.
DOI : 10.1200/JCO.2003.10.100

S. Lord, W. Lel, and P. Craft, A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer, European Journal of Cancer, vol.43, issue.13, pp.1905-1922, 2007.
DOI : 10.1016/j.ejca.2007.06.007

J. Lee, D. Kopans, and P. Mcmahon, Mutation Carriers: Effectiveness of MR Imaging???Markov Monte Carlo Decision Analysis, Radiology, vol.246, issue.3, pp.763-71, 2008.
DOI : 10.1148/radiol.2463070224

U. Menon, A. Gentry-maharaj, and R. Hallett, Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), The Lancet Oncology, vol.10, issue.4, pp.327-367, 2009.
DOI : 10.1016/S1470-2045(09)70026-9

S. Domchek, T. Friebel, and S. Neuhausen, Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study, The Lancet Oncology, vol.7, issue.3, pp.223-232, 2006.
DOI : 10.1016/S1470-2045(06)70585-X

S. Narod, H. Risch, and R. Moslehi, Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group, N Engl J Med Aug, vol.13339, issue.7, pp.424-432, 1998.

U. Beck and M. Ritter, Risk Society, 2004.
DOI : 10.4135/9781412952552.n244

URL : https://hal.archives-ouvertes.fr/halshs-00795250

N. Jacobson, The socially constructed breast: breast implants and the medical construction of need., American Journal of Public Health, vol.88, issue.8, pp.1254-61, 1998.
DOI : 10.2105/AJPH.88.8.1254

A. Eisen and B. Weber, Prophylactic Mastectomy ??? The Price of Fear, New England Journal of Medicine, vol.340, issue.2, pp.137-138, 1999.
DOI : 10.1056/NEJM199901143400209

A. Jonsen, S. Durfy, W. Burke, and A. Motulsky, The advent of the ???unpatients???, Nature Medicine, vol.327, issue.6, pp.622-626, 1996.
DOI : 10.1056/NEJM199211123272001

F. Eisinger, Prophylactic mastectomy: ethical issues, British Medical Bulletin, vol.81, issue.1, pp.7-19, 2007.
DOI : 10.1093/bmb/ldm003

URL : https://academic.oup.com/bmb/article-pdf/81-82/1/7/793589/ldm003.pdf

R. Keeney, Understanding Life-Threatening Risks, Risk Analysis, vol.248, issue.2, pp.627-637, 1995.
DOI : 10.1007/978-1-4899-0445-4_9

F. Eisinger, Bases théoriques des interventions de chirurgie prophylactique

A. Monteiro, BRCA1: the enigma of tissue-specific tumor development, Trends in Genetics, vol.19, issue.6
DOI : 10.1016/S0168-9525(03)00110-0

M. Noruzinia, I. Coupier, and P. Pujol, IsBRCA1/BRCA2-related breast carcinogenesis estrogen dependent?, Cancer, vol.24, issue.8, pp.1567-74, 2005.
DOI : 10.1093/jnci/94.19.1504-a

URL : http://onlinelibrary.wiley.com/doi/10.1002/cncr.21367/pdf

T. Powles, Tamoxifen and familial breast cancer. Tumor prevention and genetics (S15), Eur J Cancer, vol.38, issue.1, p.18, 2002.
DOI : 10.1016/s0959-8049(02)80015-6

W. Foulkes, K. Metcalfe, and P. Sun, -Related Breast Cancer, Clinical Cancer Research, vol.10, issue.6, pp.2029-2063, 2004.
DOI : 10.1158/1078-0432.CCR-03-1061

L. Seery, J. Knowlen, and J. Gee, BRCA1 expression levels predict distant metastasis of sporadic breast cancers, International Journal of Cancer, vol.79, issue.3, pp.258-62, 1999.
DOI : 10.1002/ajmg.1320560305

S. Taieb, P. Vennin, and J. Peyrat, Haut risque de cancer mammaire :quelle surveillance ?, Gynécologie& Obstétrique Pratique, vol.28, 2008.

K. Rhiem, D. Foth, and B. Wappenschmidt, Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers, Archives of Gynecology and Obstetrics, vol.101, issue.3, pp.623-630, 2011.
DOI : 10.1093/jnci/djn442

R. Love and J. Philips, Oophorectomy for breast cancer: History revisited. J Natl Cancer Inst9, pp.1433-1467, 2002.
DOI : 10.1093/jnci/94.19.1433

URL : https://academic.oup.com/jnci/article-pdf/94/19/1433/9849222/1433.pdf

A. Liber, OVARIAN CANCER IN MOTHER AND FIVE DAUGHTERS, Obstetrical & Gynecological Survey, vol.6, issue.2, pp.280-90, 1950.
DOI : 10.1097/00006254-195104000-00057

M. Feinlab, Breast cancer and artificial menopause: A cohort study, J Natl Cancer Inst, vol.41, pp.315-344, 1968.

L. Brinton, C. Schairer, and R. Hoover, Menstrual Factors and Risk of Breast Cancer, Cancer Investigation, vol.41, issue.3
DOI : 10.1016/0021-9681(72)90169-5

J. Tobaccman, M. Greene, and M. Tucker, INTRA-ABDOMINAL CARCINOMATOSIS AFTER PROPHYLACTIC OOPHORECTOMY IN OVARIAN-CANCER-PRONE FAMILIES, The Lancet, vol.320, issue.8302, pp.795-802, 1982.
DOI : 10.1016/S0140-6736(82)92681-2

M. Piver, M. Jishi, and Y. Tsukada, Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer: A report of the

S. Narod, P. Sun, and P. Ghadirian, Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study, The Lancet, vol.357, issue.9267, pp.1467-70
DOI : 10.1016/S0140-6736(00)04642-0

K. Helzlsouer, Bad News/Good News: Information About Breast Cancer Risk Following Prophylactic Oophorectomy, JNCI Journal of the National Cancer Institute, vol.350, issue.9084, 1999.
DOI : 10.1016/S0140-6736(97)08233-0

URL : https://academic.oup.com/jnci/article-pdf/91/17/1442/7795083/1442.pdf

O. Johannsson, N. Loman, and A. Borg, Pregnancy-associated breast cancer in BRCA1 and BRCA2 germline mutation carriers, The Lancet, vol.352, issue.9137, pp.1359-60, 1998.
DOI : 10.1016/S0140-6736(05)60750-7

T. Rebbeck, Y. Wang, and P. Kantoff, Modification of BRCA1 and BRCA2- associated breast cancer risk by AIB1 genotype and reproductive history, Cancer Res, vol.61, pp.5420-5444, 2001.

T. Vu and N. , Traitement_terminé (THM) 1= oui 2=non Si oui, date de fin de traiement par, 2011.